ClinicalTrials.gg
RecruitingNCT07353424SALACUNARUpdated Jan 20, 2026

A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts (SALACUNAR)

An interventional study of B-salicornia in Lacunar Stroke, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Study summary

SALACUNAR (LACI-2-polyphenols) is a multi-center randomized controlled trial (RCT) to evaluate the effect of a polyphenol-rich supplement on small vessel neurovascular disease. Specifically, the compound to be tested is a dietary supplement based on Salicornia extract and B vitamins (B-salicornia), which in previous studies has demonstrated a good safety profile and consistent effects in reducing homocysteine levels and improving cognitive outcomes (MOCA) in patients with lacunar infarcts. This has been used to calculate the sample size based on these endpoints. Considering an intragroup variability of the treatment groups (sigma) of 6.07, and accepting an alpha risk of 0.05, a sample of 150 patients per group would achieve a 1-beta statistical power greater than 0.8 in a two-tailed test for differences between means of at least two points on the MOCA scale.

Three hundred patients with lacunar infarcts diagnosed within the last year and confirmed by MRI performed as part of routine clinical practice will be included.

We will administer 500 mg/24 h of the dietary supplement B-Salicornia for six months (or the control group will be managed according to routine clinical practice) following a PROBE design.

Routine blood tests will be performed pre- and post-treatment, with routine vascular parameters such as lipids and homocysteine, as well as baseline and six-month assessments of neuropsychological and gait scales.

02

Conditions studied

  • Lacunar Stroke

Browse trials for

Keywords

  • attack
  • food supplement
  • cognition
03

In context

Stroke, Lacunar

21 studies on the registry are indexed under Stroke, Lacunar; 9 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 15 interventional studies indexed under Stroke, Lacunar.

Browse Stroke, Lacunar studies →

Lead sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla is the lead sponsor of 120 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients with lacunar ischemic stroke, confirmed by cranial magnetic resonance imaging performed within the year prior to inclusion, who have an mRS of 3 or less at the time of inclusion will be included (independent patients or those who require assistance with walking). The inclusion age will be between 40 and 90 years.

Exclusion criteria

Exclusion Criteria:

  • Consumption of vitamin supplements or polyphenol supplements within 30 days prior to inclusion
  • Hyperthyroidism
  • mRS >3, serious illness, or expected \<12 months
  • Dysphagia preventing intake of the study capsules
  • Allergies or intolerance to halophytes
  • Pregnant or breastfeeding
  • Active neoplasia
  • Participation in another study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Treatment

    Food supplement to be taken once a day.

    Dietary Supplement: B-salicornia

  • No intervention
    Clinical practice

    Without intervention

Interventions

  • Dietary supplementB-salicornia

    Dietary supplement based on halophyte plant extracts (experimental) plus regular medical treatment. Dosage: once daily. Duration of study: 6 months.

06

What researchers measure

Primary outcomes

  1. Six-minute walk test (6MWT)

    To evaluate changes in walking performance in patients who took the supplement compared to patients who followed standard clinical practice.

    Time frame: 6 months

  2. Neuropsychological questionnaires: Montreal Cognitive Assessment (MOCA)

    Assess possible improvements in cognitive function in patients taking the supplement versus patients following standard clinical practice.

    Time frame: 6 months

  3. Blood laboratory parameters (homocysteine µmol/L).

    Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.

    Time frame: 6 months

  4. Morisky-Green test count of returned treatment capsules.

    Confirm adequate adherence to dietary supplementation.

    Time frame: 6 months

  5. Severity of the adverse event.

    \- Mild: No antidote or treatment required; brief hospitalisation. - MODERATE: Treatment modification required (e.g., dose change, addition of another drug), but discontinuation of the drug is not essential; prolonged administration of the drug is not essential; prolonged hospitalisation or treatment may be necessary, or specific hospitalisation or treatment may be necessary. - SEVERE: The adverse drug reaction is life-threatening and requires discontinuation of the drug. Drug administration should be discontinued and specific treatment instituted. - FATAL: An adverse drug reaction may directly or indirectly contribute to the death of the patient.

    Time frame: 6 months

Secondary outcomes

  1. Blood laboratory parameters (total cholesterol mg/dl).

    Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.

    Time frame: 6 months

  2. Blood laboratory parameters (Low density lipoprotein cholesterol mg/dl).

    Measurement of changes in blood tests in patients taking the dietary supplement compared to patients following standard clinical practice.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Jan 20, 2026
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07353424
Collaborators
Joan Montaner Villalonga
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jun 1, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

CRISTINA LÓPEZ AZCÁRATE
Contact
Salacunar@gmail.com
+34608114878
CARMEN DOMÍNGUEZ RUIZ
Contact
Salacunar@gmail.com
+34608114878

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion